Primary headache disorders
Five new things
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 3, 2019
- Accepted April 17, 2019
- First Published May 17, 2019.
Article Versions
- Previous version (May 17, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Peter J. Goadsby
- Peter J. Goadsby
I have consulted for the following commercial entities Alder Bio Allergan Amgen Autonomic Technologies Inc Dr Reddy's Laboratories Eli-Lilly Electrocore LLC eNeura Inc Novartis Scion Teva Pharmaceuticals Trigemina
NONE
NONE
Up-to-Date Massachusetts Medical Society
NONE
Lance JW, Goadsby PJ. Mechanism and Management of Headache. (7th ed.) New York: Elsevier, 2005
NONE
NONE
NONE
NONE
NONE
Amgen, Eli-Lilly
NONE
NONE
NONE
Trigemina, Inc, stock options
NONE
NONE
NONE
NONE
MedicoLegal work
- NIHR-Wellcome Trust King's Clinical Research Facility and SLaM Biomedical Research Centre, King's College London, UK; and Department of Neurology, University of California, San Francisco.
- Correspondence
Dr. Goadsby peter.goadsby{at}kcl.ac.uk
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- What can you give me for my migraine? I cannot take triptans. Gepants or Ditans?
- I have too many migraines: I will give you a migraine preventive
- I do not want another pill for my migraine: I have nonpill options
- Please help me; I have cluster headache: Yes, I can do that
- Should I avoid chocolate to prevent my migraine: No!
- Conclusion
- Author contributions
- Study funding
- Disclosure
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineEva Cernuda-Morollón, Davinia Larrosa, César Ramón et al.Neurology, August 23, 2013 -
Article
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapyKathleen Mullin, David Kudrow, Robert Croop et al.Neurology, January 13, 2020 -
Editorial
Is CGRP a marker for chronic migraine?Stephen D. Silberstein, Lars Edvinsson et al.Neurology, August 23, 2013 -
What's Happening
What's happening in Neurology® Clinical Practiceet al.Neurology, June 15, 2020